Compare Amgen, Inc. (AMGN) vs Old Dominion Freight Line Inc (ODFL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Old Dominion Freight Line Inc — how do they compare? Amgen, Inc. trades at $414.39 (market cap $224.14B), while Old Dominion Freight Line Inc trades at $210.85 (market cap $43.43B). The key difference: Amgen, Inc. is far larger — about 5.2× Old Dominion Freight Line Inc's market cap, and Amgen, Inc. pays the higher dividend (2.43%). Which is the better fit depends on your goals.
| AMGN | ODFL | |
|---|---|---|
Market Cap | $224.14B | $43.43B |
Sector | Health | Industrials |
52-Week High | $417.20 | $248.73 |
52-Week Low | $271.18 | $126.29 |
Enterprise Value | $267.45B | $43.17B |
Dividend Yield | 2.43% | 0.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
ODFL trades at $212.55, down 1.76% today, with a bearish technical signal despite recent earnings beats. The company maintains strong profitability with 19.44% net margins and 24.82% ROE, though valuation metrics remain elevated with a P/E of 40.28. Recent Q2 2026 earnings of $1.68 per share exceeded expectations, driven by yield improvements and cost discipline amid ongoing freight market pressures.
The stock faces headwinds from premium valuation and mixed analyst sentiment (33% buy, 56% hold), but strong fundamentals and consistent earnings outperformance provide support. Key risks include freight volume recovery uncertainty and execution pressure given high expectations. The consensus price target of $239.85 suggests 13% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Old Dominion Freight Line Inc
Old Dominion Freight Line is the fourth-largest less-than-truckload carrier in the United States, with more than 240 service centers and 9,200-plus tractors. OD is by far one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns stand head and shoulders above its peers. Strategic initiatives revolve around increasing network density through market share gains and maintaining industry-leading service via consistent infrastructure investment.
Read more on ODFL →
